Global Hemophilia Drugs Market 2016-2020

  • ID: 3940973
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
1 of 5
Top 10 Vendors in the Global Hemophilia Drugs Market

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Bayer
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Grifols
  • Octapharma
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Hemophilia

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia.

To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

The analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen
- BioMarin
- Catalyst Bioscience
- Chiesi Farmaceutici
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Grifols, Kedrion Biopharma
- Octapharma
- REVO Biologics
- OPKO Biologics
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
- UniQure Biopharma.

Market drivers
- Focus on prophylactic treatment

Market challenges
- Low diagnosis rate

Market trends
- Increase in technological innovations

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Bayer
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Grifols
  • Octapharma
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Pipeline portfolio

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation by type of disease
  • Global hemophilia A drugs market
  • Global hemophilia inhibitors treatment market
  • Global hemophilia B drugs market
  • Global von Willebrand disease treatment market
PART 08: Market segmentation by type of therapy
  • Recombinant therapies
  • Plasma-derived therapies
PART 09: Market segmentation by type of disease management
  • Prophylaxis
  • On-demand therapy
  • Inhibitor therapy
PART 10: Geographical segmentation
  • Hemophilia drugs market in Americas
  • Hemophilia drugs market in EMEA
  • Hemophilia drugs market in APAC
PART 11: Market drivers
  • Focus on prophylactic treatment
  • Drugs with prolonged action
  • Improved diagnostic procedures
PART 12: Impact of drivers

PART 13: Market challenges
  • Low diagnosis rate
  • High entry barriers
  • Cost-intensive complex treatment
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Increase in technological innovations
  • Development of gene therapy products
  • Centralized buyers should pave the way to increased penetration
PART 16: Vendor landscape
  • Competitive scenario
  • Other prominent vendors
PART 17: Key vendor analysis
  • Baxalta
  • Bayer
  • CSL Behring
  • Novo Nordisk
  • Pfizer
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria for global hemophilia drugs market 2015
Exhibit 04: Key customer segments of hemophilia drugs market
Exhibit 05: Pipeline portfolio: Global hemophilia drugs market
Exhibit 06: Pipeline share of major companies
Exhibit 07: Global hemophilia drugs market snapshot: Developed and emerging markets 2015
Exhibit 08: Global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 09: Impact of factors affecting the market 2015 and 2020
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global hemophilia drugs market by disease type based on revenue 2015
Exhibit 12: Global hemophilia drugs market segmentation growth lifecycle analysis
Exhibit 13: Global hemophilia drugs market by disease type 2015-2020
Exhibit 14: Global hemophilia A drugs market 2015-2020 ($ billions)
Exhibit 15: Global hemophilia inhibitors treatment market 2015-2020 ($ billions)
Exhibit 16: Global hemophilia B drugs market 2015-2020 ($ billions)
Exhibit 17: Global von Willebrand disease treatment market 2015-2020 ($ millions)
Exhibit 18: Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015
Exhibit 19: Global hemophilia drugs market by type of therapy 2015-2020
Exhibit 20: Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 21: Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 22: Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015
Exhibit 23: Global hemophilia drugs market by geography 2015-2020
Exhibit 24: Percentage share of global hemophilia drugs market by geography 2015 and 2020
Exhibit 25: Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 26: Global share of hemophilia drugs market by geography 2015
Exhibit 27: Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 28: Global hemophilia drugs market: Country analysis based on revenue and growth rate
Exhibit 29: Opportunity analysis of hemophilia drugs market in Americas
Exhibit 30: Hemophilia drugs market in Americas 2015-2020 ($ billions)
Exhibit 31: Opportunity analysis of hemophilia drugs market in EMEA
Exhibit 32: Hemophilia drugs market in EMEA 2015-2020 ($ billions)
Exhibit 33: Opportunity analysis of hemophilia drugs market in APAC
Exhibit 34: Hemophilia drugs market in APAC 2015-2020 ($ billions)
Exhibit 35: Impact of drivers
Exhibit 36: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Gene therapies under development for hemophilia
Exhibit 39: Market share of vendors 2015
Exhibit 40: Geographical presence of key vendors
Exhibit 41: Competitive scenario of global hemophilia drugs market vendors 2015-2020
Exhibit 42: Baxalta: Strength assessment
Exhibit 43: Baxalta: Strategy assessment
Exhibit 44: Baxalta: Opportunity assessment
Exhibit 45: Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 46: Bayer: Strength assessment
Exhibit 47: Bayer: Strategy assessment
Exhibit 48: Bayer: Opportunity assessment
Exhibit 49: Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions)
Exhibit 50: CSL Behring: Strength assessment
Exhibit 51: CSL Behring strategy assessment
Exhibit 52: CSL Behring opportunity assessment
Exhibit 53: CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions)
Exhibit 54: Novo Nordisk: Strength assessment
Exhibit 55: Novo Nordisk: Strategy assessment
Exhibit 56: Novo Nordisk: Opportunity assessment
Exhibit 57: Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 58: Pfizer: Strength assessment
Exhibit 59: Pfizer: Strategy assessment
Exhibit 60: Pfizer: Opportunity assessment
Exhibit 61: Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Bayer
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Grifols
  • Octapharma
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Hemophilia Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the global hemophilia drugs market: Baxalta, Bayer, CSL Behring, Novo Nordisk, and Pfizer.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, and UniQure Biopharma.

Commenting on the report, an analyst from the research team said: “One trend gaining traction in this market is increase in technological innovations. Currently, most of the hemophilia therapeutics available in the market are short-acting i.e., used only for when the individual suffers from bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products.”

According to the report, drugs with prolonged action will drive the market. Earlier, parenteral formulations for treating hemophilia B required frequent administration of replacement factors. Drugs with favorable pharmacokinetic profiles, including prolonged mechanism of action are fast gaining acceptance among physicians and individuals. These long-acting formulations reduce the need for repeated dosing of medications, reducing injection site pain. ALPROLIX by Biogen is one such drug.

Further, the report states that the diagnosis rates of hemophilia are very low, especially in the developing countries like China and India. In the developed regions such as Germany, Australia, and the US, the disease diagnosis rate is more than 80%. However, in developing countries such as China, India, and Indonesia, disease diagnosis rates are 56%, 12%, and 4%, respectively. The low diagnosis rate of hemophilia in developing countries is due to inadequate treatment facilities, limited disease knowledge, and a shortage of treatment supplies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen
- BioMarin
- Catalyst Biosciences
- Chiesi Farmaceutici
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Grifols
- Kedrion Biopharma
- Octapharma
- rEVO Biologics
- OPKO Biologics
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
- UniQure Biopharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll